• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Protara Therapeutics Inc.

    8/11/25 5:09:27 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARA alert in real time by email
    S-8 1 ea0250539-s8_protara.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on August 11, 2025

    Registration No. 333-              

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Protara Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   20-4580525
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    345 Park Avenue South, Third Floor

    New York, NY 10010

    (Address of Principal Executive Offices) (Zip Code)

     

    2024 Equity Incentive Plan, as amended

    (Full title of the plans)

     

    Jesse Shefferman

    President and Chief Executive Officer

    Protara Therapeutics, Inc.

    345 Park Avenue South, Third Floor

    New York, NY 10010

    (Name and address of agent for service)

     

    (646) 844-0337

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Mary J. Grendell
    General Counsel and Corporate Secretary
      Robert W. Downes
    Sullivan & Cromwell LLP
    Protara Therapeutics, Inc.   125 Broad St.
    345 Park Avenue South, Third Floor   New York, NY 10004
    New York, NY 10010   (212) 558-4000
    (646) 844-0337    

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ 

     

     

     

     

     

    PART I

     

    EXPLANATORY NOTE

     

    Protara Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering an additional 2,800,000 shares of common stock (the “Common Stock”) under the Registrant’s 2024 Equity Incentive Plan, (the “2024 EIP”), pursuant to an amendment to the 2024 EIP adopted by the Registrant’s Board of Directors on April 17, 2025 and approved by the stockholders of the Registrant at the Annual Meeting held on June 11, 2025.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. Incorporation of Documents by Reference.

     

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective. The Registrant previously registered shares of its Common Stock for issuance under the 2024 EIP under Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2024 (File No. 333-281286). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

     

    The Registrant hereby also incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the SEC (other than portions of Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits related to such items or other portions of documents filed with the SEC which were furnished, but not filed, pursuant to applicable rules promulgated by the SEC):

     

    ●the Company’s Annual Report on Form 10-K filed with the SEC on March 5, 2025; and

     

    ●the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 filed with the SEC on May 8, 2025 and August 11, 2025, respectively; and

     

    ●the Company’s Current Reports on Form 8-K filed on January 13, 2025 (solely to the extent of Item 8.01 thereof), April 28, 2025 (solely to the extent of Item 8.01 thereof), and June 12, 2025; and

     

    ●the description of the Company’s Common Stock contained in Exhibit 4.2 to the Company’s Annual Report on Form 10-K filed with the SEC on March 11, 2021, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    ITEM 4. Description of Securities.

     

    Not applicable.

     

    ITEM 5. Interests and Named Experts and Counsel.

     

    Not applicable.

     

    II-1

     

     

    ITEM 6. Indemnification of Directors and Officers.  

     

    The Registrant’s certificate of incorporation and bylaws provide for indemnification of the Registrant’s directors and officers to the fullest extent permitted by law. Insofar as indemnification for liabilities under the Securities Act of 1933 may be permitted to directors, officers or controlling persons of the Registrant pursuant to the Registrant’s certificate of incorporation, bylaws and the Delaware General Corporation Law, or DGCL, the Registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Section 102(b)(7) of the DGCL provides that a certificate of incorporation may include a provision that eliminates or limits the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, relating to prohibited dividends or distributions or the repurchase or redemption of stock or (iv) for any transaction from which the director derives an improper personal benefit. The Registrant’s certificate of incorporation includes such a provision. As a result of this provision, the Registrant and its stockholders may be unable to obtain monetary damages from a director for breach of his or her duty of care.

     

    As permitted under the DGCL, the Registrant has entered into indemnification agreements with each of its directors and executive officers that require the Registrant to indemnify such persons against any and all expenses (including attorneys’, witness or other professional fees), and unless in connection with a proceeding by or in the right of the Registrant, any and all judgments, fines and amounts paid in settlement, actually and reasonably incurred by such persons or on such persons’ behalf in connection with any proceeding, whether actual or threatened, to which any such person may be involved as a party or otherwise by reason of the fact that such person is or was a director or an executive officer of the Registrant or is or was serving at the request of the Registrant as a director, officer, employee, agent or fiduciary of another enterprise, provided such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful. Under these agreements, the Registrant is not required to provide indemnification for certain matters, including:

     

    ●indemnification beyond that permitted by applicable law;

     

    ●except as provided in the indemnification agreements, an accounting of profits made from the purchase and sale (or sale and purchase) by such director or executive officer of securities of the Registrant within the meaning of Section 16(b) of the Securities Exchange Act of 1934 or similar provisions of state statutory law or common law;

     

    ●except as provided in the indemnification agreements, any reimbursement of the Registrant by such director or executive officer of any bonus or other incentive-based or equity-based compensation or of any profits realized by such director or executive officer from the sale of securities of the Registrant, as required in each case under the Exchange Act; or

     

    ●except as provided in the indemnification agreements, any reimbursement of the Registrant by such director or executive officer of any bonus or other incentive-based or equity-based compensation or of any profits realized by such director or executive officer from the sale of securities of the Registrant, as required in each case under the Exchange Act; or

     

    ●except as provided in the indemnification agreements, in connection with any proceeding initiated by such director or executive officer, unless (i) the Registrant’s board of directors authorized the proceeding prior to its initiation or (ii) the Registrant provides the indemnification, in its sole discretion, pursuant to the powers vested in the Registrant under applicable law.

      

    The indemnification agreements also set forth certain procedures, presumptions and remedies that will apply in the event of a claim for indemnification thereunder.

     

     ITEM 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    II-2

     

     

    ITEM 8. Exhibits.

     

    Exhibit
    Number
      Description
         
    4.1   Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on October 27, 2014).
         
    4.2   Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on January 10, 2020).
         
    4.3   Second Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on May 13, 2020).
         
    4.4   Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on August 3, 2017).
         
    4.5   Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on January 10, 2020).
         
    4.6   Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 23, 2020).
         
    4.7   Registration Rights Agreement, dated as of September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K, filed with the Commission on September 24, 2019).
         
    4.8   Registration Rights Agreement, dated April 5, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K, filed with the Commission on April 5, 2024).
         
    4.9   Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on January 10, 2020).
         
    5.1*   Opinion of Sullivan & Cromwell LLP.
         
    23.1*   Consent of Ernst & Young LLP.
         
    23.2*   Consent of Sullivan & Cromwell LLP (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on signature page).
         
    99.1   2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 6, 2024).
         
    99.2   2024 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 11, 2025). 
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

    II-3

     

     

    ITEM 9. Undertakings.

     

    The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on August 11, 2025.

     

      PROTARA THERAPEUTICS, INC.
         
      By: /s/ Jesse Shefferman
        Jesse Shefferman
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jesse Shefferman, Patrick Fabbio and Mary J. Grendell, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

     

    Signature   Title   Date
             
    /s/ Jesse Shefferman   President and Chief Executive Officer and Director   August 11, 2025
    Jesse Shefferman   (Principal Executive Officer)    
             
    /s/ Patrick Fabbio   Chief Financial Officer   August 11, 2025
    Patrick Fabbio   (Principal Financial Officer)    
             
    /s/ Hannah Fry   Vice President, Controller   August 11, 2025
    Hannah Fry   (Principal Accounting Officer)    
             
    /s/ Luke Beshar   Chairman of the Board of Directors   August 11, 2025
    Luke Beshar        
             
    /s/ Barry Flannelly   Director   August 11, 2025
    Barry Flannelly, Pharm.D.        
             
    /s/ Roger Garceau   Director   August 11, 2025
    Roger Garceau, M.D.        
             
    /s/ Jane Huang   Director   August 11, 2025
    Jane Huang, M.D.        
             
    /s/ Richard Levy   Director   August 11, 2025
    Richard Levy, M.D.        
             
    /s/ Gregory P. Sargen   Director   August 11, 2025
    Gregory P. Sargen        
             
    /s/ Cynthia Smith   Director   August 11, 2025
    Cynthia Smith        
             
    /s/ Michael Solomon   Director   August 11, 2025
    Michael Solomon, Ph.D.        

     

    II-5

    Get the next $TARA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TARA

    DatePrice TargetRatingAnalyst
    4/16/2025$12.00Sector Outperform
    Scotiabank
    3/14/2025Overweight
    Cantor Fitzgerald
    7/10/2023$22.00Buy
    Guggenheim
    11/8/2021$32.00 → $34.00Outperform
    Oppenheimer
    More analyst ratings

    $TARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Protara Therapeutics with a new price target

    Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    4/16/25 8:13:38 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Protara Therapeutics

    Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight

    3/14/25 7:42:48 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim resumed coverage on Protara Therapeutics with a new price target

    Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00

    7/10/23 7:28:47 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Shefferman Jesse gifted 300,000 shares (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    7/7/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and President Shefferman Jesse gifted 18,667 shares, decreasing direct ownership by 2% to 959,886 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    6/30/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Sargen Gregory

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    6/13/25 4:05:27 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Leadership Updates

    Live Leadership Updates

    View All

    Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com

    8/11/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Addition to the Russell 3000® Index

    NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid

    6/30/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

    NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

    6/2/25 4:04:01 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Financials

    Live finance-specific insights

    View All

    Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

    TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patientsFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsOn track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company

    4/26/25 10:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

    NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025, to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), including data from patients who have reached the 12-month evaluation timepoint. The data will be featured during an interactive poster session at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2

    4/23/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

    TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at

    12/5/24 7:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/19/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/16/25 4:05:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 6,200 stock option awards and 3,100 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on September 2,

    9/2/25 4:05:06 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Participate in Upcoming Investor Conferences

    NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference. A fireside chat will take place on Thursday, September 4, 2025 at 1:35 pm ET in New York.H.C. Wainwright 27th Annual Global Investment Conference. A corporate presentation will take place on Tuesday, September 9, 2025 at 9:00 am ET in New York. A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.p

    8/27/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com

    8/11/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

    SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

    8/14/25 6:03:25 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.

    SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)

    8/14/25 11:15:32 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Protara Therapeutics Inc.

    S-8 - Protara Therapeutics, Inc. (0001359931) (Filer)

    8/11/25 5:09:27 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    12/17/24 4:02:03 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/18/24 6:01:42 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/14/24 1:00:40 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care